Savara (NASDAQ:SVRA) was downgraded by equities research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Thursday.
SVRA has been the topic of several other reports. BidaskClub lowered shares of Savara from a “buy” rating to a “hold” rating in a research note on Friday, January 19th. Canaccord Genuity set a $25.00 price objective on shares of Savara and gave the stock a “buy” rating in a research note on Friday, February 16th. Ladenburg Thalmann Financial Services began coverage on shares of Savara in a research note on Wednesday, January 3rd. They set a “buy” rating and a $35.00 price objective on the stock. Finally, Zacks Investment Research lowered shares of Savara from a “buy” rating to a “hold” rating in a research note on Thursday, November 23rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Savara presently has a consensus rating of “Hold” and an average target price of $23.58.
Savara (NASDAQ:SVRA) traded down $0.07 during trading on Thursday, hitting $11.05. 211,679 shares of the stock traded hands, compared to its average volume of 157,661. The firm has a market cap of $337.03, a price-to-earnings ratio of -3.29 and a beta of -0.26. Savara has a one year low of $4.60 and a one year high of $17.19. The company has a quick ratio of 9.15, a current ratio of 9.15 and a debt-to-equity ratio of 0.20.
A number of institutional investors and hedge funds have recently made changes to their positions in SVRA. Consonance Capital Management LP acquired a new position in Savara in the 4th quarter valued at about $40,899,000. VHCP Management II LLC acquired a new position in Savara in the 4th quarter valued at about $18,691,000. BlackRock Inc. grew its stake in Savara by 642.4% in the 4th quarter. BlackRock Inc. now owns 499,512 shares of the company’s stock valued at $7,412,000 after buying an additional 432,225 shares during the last quarter. Lyon Street Capital LLC grew its stake in Savara by 53.4% in the 4th quarter. Lyon Street Capital LLC now owns 779,554 shares of the company’s stock valued at $11,569,000 after buying an additional 271,214 shares during the last quarter. Finally, Sectoral Asset Management Inc acquired a new position in Savara in the 4th quarter valued at about $2,374,000. Institutional investors and hedge funds own 24.71% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3231849/savara-svra-stock-rating-lowered-by-valuengine.html.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.